PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2006.38.4.2012006384201Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as Second Line TherapyDuk-Joo Lee, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Myung-Ju Ahnhttp://www.e-crt.org/upload/pdf/crt-38-201.pdf, http://www.e-crt.org/upload/pdf/crt-38-201.pdf
OncoTargets and Therapy10.2147/ott.s8144220151061A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutationLijuan Luan, Yuguo Liu, Lijuan Luanhttps://www.dovepress.com/getfile.php?fileID=25044
Cancer Research and Treatment10.4143/crt.2004.36.4.2352004364235Phase II Study of Irinotecan, 5-Fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as First-line TherapyYoung-Woong Won, Young-Hyo Lim, Ho-Yong Park, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Myung-Ju Ahnhttp://www.e-crt.org/upload/pdf/crt-36-235.pdf, http://www.e-crt.org/upload/pdf/crt-36-235.pdf
Clinical Colorectal Cancer10.3816/ccc.2007.n.033200769646-651Phase II Trial of 5-Fluorouracil/Leucovorin/Gemcitabine/Cisplatin as Second-Line Treatment in Patients with Metastatic or Recurrent Colorectal Carcinoma: A Cancer Therapeutics Research Group StudyAlex Y. Chang, Gilberto Lopes, Koo Wen Hsin, Robert Lim, Foo Kian Fong, John Wonghttps://api.elsevier.com/content/article/PII:S153300281170305X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S153300281170305X?httpAccept=text/plain
Clinical Colorectal Cancer10.3816/ccc.2007.n.017200767516-521Phase II Trial of Oxaliplatin/Irinotecan/5-Fluorouracil/Leucovorin for Metastatic Colorectal CancerRobert R. McWilliams, Matthew P. Goetz, Bruce W. Morlan, Muhammad Salim, Kendrith M. Rowland, James E. Krook, Matthew M. Ames, Charles Erlichmanhttps://api.elsevier.com/content/article/PII:S1533002811702936?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1533002811702936?httpAccept=text/plain
Clinical Colorectal Cancer10.3816/ccc.2010.n.021201093157-161A Phase II Study of Oxaliplatin, 5-Fluorouracil, Leucovorin, and High-Dose Capecitabine in Patients With Metastatic Colorectal CancerSam J. Lubner, Noelle K. LoConte, Kyle D. Holen, William Schelman, James P. Thomas, Alcee Jumonville, Jens C. Eickhoff, Songwon Seo, Daniel L. Mulkerinhttps://api.elsevier.com/content/article/PII:S1533002811700512?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1533002811700512?httpAccept=text/plain
Cancer Management and Research10.2147/cmar.s6140820151655-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb studyJ. Randolph Hecht, Edith Mitchell, Takayuki Yoshino, Manfred Welslau, Xun Lin, Edna Chow Maneval, Jolanda Paolini, Maria Jose Lechuga, Albrecht Kretzschmarhttps://www.dovepress.com/getfile.php?fileID=25492
European Journal of Cancer10.1016/s0959-8049(02)80877-2200238S72A Phase II Study of ANGIOZYME® in combination with 5-fluorouracil, leucovorin and ironotecan in the treatment of metastatic colorectal cancer patientshttps://api.elsevier.com/content/article/PII:S0959804902808772?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0959804902808772?httpAccept=text/plain
European Journal of Cancer Supplements10.1016/s1359-6349(05)81035-3200532211-212740 POSTER Fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first line therapy in patients with advanced gastric cancer —interim analysis of a multicenter, randomized phase II trialhttps://api.elsevier.com/content/article/PII:S1359634905810353?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634905810353?httpAccept=text/plain
Medical Oncology10.1007/s12032-014-0325-92014321A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancerRanhua Cao, Shuai Zhang, Dedong Ma, Likuan Huhttp://link.springer.com/content/pdf/10.1007/s12032-014-0325-9.pdf, http://link.springer.com/article/10.1007/s12032-014-0325-9/fulltext.html, http://link.springer.com/content/pdf/10.1007/s12032-014-0325-9